Cervical Cancer Clinical Trial
Official title:
Multicenter Open-Label Single-Arm Trial of the Efficacy and Safety of BCD-100 in Combination With Platinum-Based Chemotherapy and Bevacizumab as First Line Treatment in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Verified date | May 2019 |
Source | Biocad |
Contact | Mariia S Shustova, MD |
Phone | +7-(812)-380-49-33 |
biocad[@]biocad.ru | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, open-label, single-arm study of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) in combination with platinum-based chemotherapy and bevacizumab as first-line treatment in patients with recurrent/persistent or metastatic cervical cancer.
Status | Recruiting |
Enrollment | 49 |
Est. completion date | July 7, 2020 |
Est. primary completion date | July 7, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Signed Informed Consent Form and the subject's ability to follow the Protocol requirements; 2. Age: 18 years and older at the signing of the informed consent; 3. Histologically verified (documented) adenomatous, adenosquamous, or squamous cervical cancer; 4. Newly diagnosed metastatic cervical cancer or recurrent/persistent cervical cancer; 5. Availability of archival histological tumor material (paraffin blocks) or consent to biopsy; 6. ECOG performance status of 0 or 1; 7. At least one RESICT 1.1-defined measurable target lesion confirmed by an independent review; 8. Patients with reproductive potential must agree to practice acceptable methods of birth control throughout the entire trial period, starting from signing the informed consent and up to 24 weeks after the last dose of investigational product. Exclusion Criteria: 1. Indications for radical therapy (surgical or radiotherapy); 2. Prior systemic treatment for recurrent, secondarily progressive or initially metastatic disease; 3. Chemotherapy, and / or radiation therapy, and / or chemo-radiation therapy for early stages of cervical cancer with disease progression / recurrence earlier than 6 months after the end of therapy; 4. Patients with severe concomitant factors or the effects of their treatment (hemorrhage, perforation, fistula); 5. Central nervous system (CNS) metastases; 6. Concomitant diseases or conditions which pose a risk of AE development during study treatment: 1. uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg; 2. stable angina functional class III-IV; 3. unstable angina or myocardial infarction less than 6 months prior to randomization; 4. NYHA Grade III-IV congestive heart failure; 5. atopic asthma, Stage III-IV COPD, angioedema; 6. severe respiratory failure; 7. any other diseases which pose unacceptable risk of AE development during study treatment in Investigator's opinion; 7. Active or known or suspected autoimmune disease (subjects with Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll); 8. Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days prior to randomization; 9. Established diagnosis of coagulopathy and / or clinically significant bleeding, including nasal bleeding; 10. The need for regular intake of anticoagulants, antiplatelet agents, platelet function inhibitors, or their course application less than 1 month before being included in the study; 11. Hematologic disorders: neutrophils <1500/mcl or platelets <100 000/mcl or hemoglobin <90 g/l; 12. Renal disorders: creatinine = 1.5 x UNL; 13. Hepatic disorders: bilirubin = 1.5 x UNL (excluding Gilbert's syndrome if bilirubin < 50 µmol/l) or AST/ALT = 3 x UNL (excluding subjects with liver metastases if AST/ALT < 5 x UNL) or alkaline phosphatase = 5 x UNL; 14. Any anti-cancer therapy less than 28 days prior to randomization; 15. Previous use of PD-1/PD-L1/PD-L2/CTLA-4 agent; 16. Previous use of VEGF/VEGFR inhibitors, including bevacizumab, ramucirumab, aflibercept and tyrosine kinase inhibitors; 17. Concomitant cancer (except for cervical carcinoma in situ after radical surgery or basal cell/ squamous cell carcinoma after radical surgery); 18. Clinically significant (=2 degree) peripheral neuropathy or hearing impairment; 19. Any condition that prevents a patient from following the Protocol procedures (dementia, neurological or mental disorders, drug/alcohol abuse, etc.); 20. Simultaneous participation in other clinical trials , participation in other clinical trials within 30 days prior to the first dose of the investigational product; 21. Acute infection or the acute phase of chronic infection within 28 days prior the first dose of the investigational product; 22. Active HBV/HCV/HIV infection, active syphilis; 23. Patients unable to receive an IV infusions; 24. Patients unable to receive an IV contrast agent; 25. Hypersensitivity to any of the components of BCD-100, bevacizumab, paclitaxel, cisplatin (or carboplatin); 26. Life expectancy less than 6 months; 27. Significant adverse events (AE) of previous therapy excluding chronic and/or irreversible events which cannot affect study drug safety evaluation (e.g. alopecia); 28. Pregnancy or breast-feeding. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Arkhangelsk Clinical Oncology Dispensary | Arkhangel'sk | Arkhangelsk Oblast |
Russian Federation | City Hospital No. 5 | Barnaul | Altai Krai |
Russian Federation | Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine | Chelyabinsk | Chelyabinsk Oblast |
Russian Federation | Sverdlovsk Regional Oncology Center | Ekaterinburg | Sverdlovsk Oblast |
Russian Federation | Republican Clinical Oncology Cente | Kazan | Republic Of Tatarstan |
Russian Federation | Clinical Oncologic Dispensary No. 1 | Krasnodar | Krasnodar Kari |
Russian Federation | Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky | Krasnoyarsk | Krasnoyarsk Krai |
Russian Federation | JSC "Medsi Group of Companies" | Moscow | |
Russian Federation | Moscow City Oncology Hospital No. 62 | Moscow | |
Russian Federation | Moscow Clinical Scientific and Practical Center named A.S. Loginova | Moscow | |
Russian Federation | N.N. Blokhin National Medical Research Center of Oncology | Moscow | |
Russian Federation | N.N. Blokhin National Medical Research Center of Oncology (2) | Moscow | |
Russian Federation | Murmansk Regional Clinical Hospital named after P.A. Bayandina | Murmansk | Murmansk Oblast |
Russian Federation | National Medical Radiology Research Center | Obninsk | Kaluga Oblast |
Russian Federation | Clinical Oncology Dispensary | Omsk | Omsk Oblast |
Russian Federation | LLC "New Clinic" | Pyatigorsk | Stavropol Krai |
Russian Federation | JSC "Modern Medical Technologies" | Saint Petersburg | |
Russian Federation | LLC "AB Medical Group" | Saint Petersburg | |
Russian Federation | N.N. Petrov National Medical Research Center of Oncology | Saint Petersburg | |
Russian Federation | N.N. Petrov National Medical Research Center of Oncology (2) | Saint Petersburg | Saint-Petersburg |
Russian Federation | Saint-Petersburg Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) | Saint Petersburg | |
Russian Federation | Republican Oncology Center | Saransk | Republic Of Mordovia |
Russian Federation | Stavropol Regional Clinical Oncology Center | Stavropol' | Stavropol Krai |
Russian Federation | Regional Clinical Oncology Hospital | Yaroslavl | Yaroslavskaya Oblast |
Lead Sponsor | Collaborator |
---|---|
Biocad |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate (ORR) | ORR is defined as the percentage of the participants in the mITT population who have a Complete Response or a Partial Response. The ORR will be assessed by a blind independent central reviewer per RECIST 1.1 and iRECIST. | 6 months | |
Secondary | Median Progression-free Survival (PFS) | 1 year | ||
Secondary | 1-year Progression-free Survival (PFS) | 1 year | ||
Secondary | 1-year Overall Survival (OS) | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |